Drug intelligence / Profile preview

KLOT-1123 (EPOK Therapeutics)

Development stage: Preclinical
Lead developer: EPOK Therapeutics
Modality: Antibody-Based Therapeutics

Overview

KLOT-1123 is an investigational antibody developed by EPOK Therapeutics, Inc. It is uniquely engineered to selectively inhibit Fibroblast Growth Factor 23 (FGF23) signaling without reducing circulating FGF23 levels. This mechanism aims to provide a more targeted and physiologically balanced treatment for phosphate wasting disorders by preserving FGF23's essential biological roles while curbing its pathological activity. The drug is currently in preclinical development for indications such as hypophosphatemic rickets, XLH, ADHR, ARHR1-3, and TIO.

Targets

FGF23 (Fibroblast growth factor 23)

Beyond the preview

Go deeper on KLOT-1123 (EPOK Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLOT-1123 (EPOK Therapeutics).

Explore the full profile